A Phase 1 Study of R-CHOP Plus SYK Inhibitor TAK-659 for the Front-Line Treatment of High-Risk Diffuse Large B Cell Lymphoma (DLBCL)
Phase of Trial: Phase I
Latest Information Update: 20 Mar 2019
Price : $35 *
At a glance
- Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Mivavotinib (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- 13 Mar 2019 Planned End Date changed from 1 Aug 2021 to 1 Aug 2022.
- 13 Mar 2019 Planned primary completion date changed from 1 Aug 2020 to 1 Aug 2021.
- 13 Mar 2019 Status changed from not yet recruiting to recruiting.